Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed Incorporated (Nasdaq: INSM) will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call for investors is scheduled for 8:30 a.m. ET on the same day to discuss these results and provide a business update. Interested parties can join the call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international), or by accessing the live webcast on the company's website. A replay will be available shortly after the event until March 25, 2023. Insmed is focused on serious and rare diseases, with its first therapy already approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq: INSM) announced its participation in a fireside chat at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 p.m. ET. The event aims to highlight Insmed's commitment to transforming lives through its innovative approaches to serious and rare diseases. The chat will be accessible via the investor relations section on the company's website and will be archived for 30 days post-event. Insmed's first product treats a debilitating lung disease, with ongoing development of therapies targeting unmet medical needs.
Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company, announced on February 3, 2023, the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase a total of 240,010 shares at an exercise price of $21.62 per share, which reflects the closing price on the grant date. These options have a 10-year term and a four-year vesting schedule. Insmed's mission focuses on transforming the lives of patients suffering from serious and rare diseases, supported by a robust pipeline of investigational therapies.
On January 20, 2023, Insmed Incorporated (NASDAQ: INSM) announced the granting of inducement awards to 10 new employees as a material inducement for their employment. The awards, approved by the Compensation Committee, comprise options to purchase 107,580 shares at an exercise price of $19.18 per share, which aligns with the Nasdaq closing price on the grant date of January 3, 2023. The options have a 10-year term with a four-year vesting schedule, incentivizing long-term employment. Insmed focuses on therapies for serious diseases and has a pipeline targeting unmet medical needs, enhancing its market position.
Insmed Incorporated reported significant updates during the 41st Annual J.P. Morgan Healthcare Conference. The company highlighted 30% expected growth in ARIKAYCE global revenues for 2022, projecting revenues of $285 to $300 million in 2023. Phase 2 data for Brensocatib in cystic fibrosis showed a clear dose-dependent response. Additionally, a 15% treatment discontinuation rate was reported in the ARISE trial, significantly lower than prior pivotal trials. The ASPEN trial reported a blended event rate of 1.12-1.15 events per patient per year.
Insmed Incorporated (Nasdaq:INSM) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2023, at 4:30 p.m. PT (7:30 p.m. ET). The session will include a presentation and a Q&A segment, which will be streamed live via the investor relations section of Insmed's website. The webcast will remain available for 30 days post-event. Insmed focuses on transforming the lives of patients with serious and rare diseases, with its first therapy approved for a chronic lung disease and a promising pipeline for unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced on December 6, 2022, the granting of inducement awards to 15 new employees as per NASDAQ Listing Rule 5635(c)(4). These awards, aimed at encouraging new hires, involve options to purchase a total of 89,730 shares of common stock at an exercise price of $19.12 per share. The options come with a 10-year term and a four-year vesting schedule, contingent on continued employment. Insmed focuses on therapies for serious and rare diseases, with a commitment to transforming patient lives.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present at the Nasdaq 47th Investor Conference in London on December 7 at 8:30 a.m. EST (1:30 p.m. GMT). The presentation will be available via a live webcast on their website, with an archive lasting 30 days post-event. Insmed is dedicated to transforming patient lives through its first commercial therapy and a pipeline aimed at major unmet medical needs, particularly in pulmonary diseases.
Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 18 new employees on November 4, 2022. This was in compliance with NASDAQ Listing Rule 5635(c)(4) and approved by the Compensation Committee. Each new employee received options to purchase a total of 127,060 shares of common stock at an exercise price of $17.50, the closing price on November 1, 2022. The options have a 10-year term with a four-year vesting schedule.
Insmed Incorporated (Nasdaq: INSM) has announced its participation in three investor conferences in November 2022. The events include:
- Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 2:35 PM ET in Rancho Palos Verdes, CA.
- Stifel 2022 Healthcare Conference on November 15, 2022, at 2:25 PM ET in New York, NY.
- Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 8:50 AM ET.